NCT02514382
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
Clinical trial condition
Lymphoproliferative Disorders
Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.
10,106 public trials
2,040 recruiting studies
Lymphoproliferative Disorders trial results
Completed
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
NCT03314922
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
- Locations
-
- Aichi Cancer Center Hospital Aichi, Japan
- National Hospital Organization Kyushu Cancer Center Fukuoka, Japan
- Cancer Institute Hospital of Jfcr Kōtoku, Japan
- Nagoya City University Hospital Nagoya, Japan
NCT03010358
- Conditions
- Anemia, B-Cell Prolymphocytic Leukemia, Chronic Disease, +36 more
- Locations
-
- OHSU Knight Cancer Institute Portland, Oregon, United States
NCT00443976
- Conditions
- Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +39 more
- Locations
-
- BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada
- Ottawa Health Research Institute - General Division Ottawa, Ontario, Canada
NCT03215524
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
- Locations
-
- Tom Baker Cancer Centre Calgary, Alberta, Canada
- CrossCancer Institute Edmonton, Alberta, Canada
- Fraser Valley Cancer Centre Surrey, British Columbia, Canada
- CancerCare Manitoba Winnipeg, Manitoba, Canada
NCT03702231
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia (CLL), Compare SHINGRIX Vaccine Response Rates, +28 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
NCT00377052
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
- Locations
-
- Cross Cancer Institute Edmonton, Alberta, Canada
- BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada
- CancerCare Manitoba Winnipeg, Manitoba, Canada
- QEII Health Sciences Center Halifax, Nova Scotia, Canada
Completed
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
NCT01652144
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
- CancerCare Manitoba Winnipeg, Manitoba, Canada
- QEII Health Sciences Centre Halifax, Nova Scotia, Canada
- Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada
- Univ. Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
NCT01627054
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
- Locations
-
- CancerCare Manitoba Winnipeg, Manitoba, Canada
- Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada
- Univ. Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
NCT02343718
- Conditions
- Central Nervous System, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- Children's and Women's Health Centre of BC Branch Vancouver, British Columbia, Canada
- Izaak Walton Killam (IWK) Health Centre Halifax, Nova Scotia, Canada
- McMaster Children's Hospital Hamilton, Ontario, Canada
- Children's Hospital of Eastern Ontario Ottawa, Ontario, Canada